Bioheart announces agreement With StemMD
Bioheart, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it has entered into an agreement with StemMD.
According to the agreement term sheet, StemMD will provide Bioheart therapies to its global network of physicians and qualified patients.
Bioheart CEO Mike Tomas noted the company has successfully been treating patients for a variety of conditions for almost 15 years.
"By combining our experiences with the regenerative network at StemMD, we will be able to provide cutting edge treatments for many indications," Tomas added.
StemMD is a regenerative medicine company focused on techniques which include stem cell, platelet rich plasma and cytokine therapy. Through these alternative therapies, a treatment plan can be developed which is tailored to a specific disease, injury or pain.
The team at StemMD has been working with a network of physicians to provide innovative therapies to patients whose experience can contribute to the development and commercialization of Bioheart's regenerative medicine products.
Source: Company Press Release
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $0